Methods
We conducted a prospective cohort study among HCWs in seven hospitals in
Baku, Azerbaijan between May 17 to December 1, 2021, to evaluate primary
series (two-dose) CoronaVac VE against symptomatic SARS-CoV-2 infection.
Participants completed weekly symptom questionnaires, provided nasal
swabs for SARS-CoV-2 RT-PCR testing when symptomatic, and provided
serology samples at enrolment that were tested for anti-spike and
anti-nucleocapsid antibodies. We estimated VE as (1 – hazard ratio)*100
using a Cox proportional hazards model with vaccination status as a
time-varying covariate.